 |
||||||
 |
 |
 |
|
|
|
|
 |
|||||
 |
|
||||
 |
|||||
 |
|
 |
|||
 |
|||||
|
|||||
| CORPORATE MISSION | Provide innovative medical devices to advance the safety, quality, and availability of blood for patients worldwide. |
| FOUNDED | 1971 |
| HEADQUARTERS | Braintree, Massachusetts, USA |
| EXECUTIVE OFFICERS | Peter Allen, President, Donor Division Brian Concannon, President, Global Markets Robert Ebbeling, Vice President, Operations Dr. Ulrich Eckert, President, Europe and Latin America Joseph Forish, VP, Human Resources Christopher Lindop, VP and Chief Financial Officer Alicia Lopez, General Counsel and VP, Administration Brad Nutter, President and Chief Executive Officer Dr. Mark Popovsky, VP, Corporate Medical Director William Still, VP and GM, Nanoscience Business and Business Development |
| STOCK SYMBOL | NYSE: HAE |
| OVERVIEW |
Haemonetics is a global leader in blood processing technology. The Company's systems support the blood donation industry as well as hospital surgical suites. For more than thirty five years, the Company has earned a solid reputation for product innovation, technical expertise, and operational excellence. Today, Haemonetics' products, internal R&D, marketing partnerships, and product acquisitions support and reflect the Company's unwavering commitment to provide safe and available blood for patient transfusions and for use in pharmaceuticals. Haemonetics is publicly traded on the New York Stock Exchange under the ticker HAE. The company employs more than 1,600 people in offices located in 16 countries. It markets its products in over 50 countries and derives revenues almost equally from Asia, Europe, and the Americas. |
|
Products and Services · News · Events · Careers · Investors · Media · Companies · Contact Us · Privacy Statement · Terms of Use · Site Map · Home © 2008, Haemonetics Corp., 400 Wood Rd., Braintree, MA, 02184, USA Tel: (800) 225-5242 || Website Design by Garfield Group |
